Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older-Reference-Cited by-同舟云学术

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Published:2021-05-21 Issue:8 Volume:17 Page:2678-2690
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Buchwald Ulrike K.¹^ORCID,Andrews Charles P.²,Ervin John³,Peterson James T.⁴,Tamms Gretchen M.¹,Krupa David⁵,Ajiboye Patrick⁵,Roalfe Lucy⁶,Krick Andrea L.¹,Sterling Tina M.¹,Wang Meihua¹,Martin Jason C.¹,Stek Jon E.¹^ORCID,Kohn Melvin A.¹,Folaranmi Temitope¹,Abeygunawardana Chitrananda¹,Hartzel Jonathan¹,Musey Luwy K.¹^ORCID,

Affiliation:

1. Merck & Co., Inc., Kenilworth, NJ, USA

2. Diagnostics Research Group, San Antonio, TX, USA

3. Alliance for Multispecialty Research, Knoxville, TN, USA

4. Foothill Family Clinic, Salt Lake City, UT, USA

5. IQVIA, Durham, NC, USA

6. University College London, London, UK

Funder

Merck Sharp & Dohme Corp

Merck

Publisher

Informa UK Limited